RxDoctor Payments Data

Carolyn Clark, NP

Family · Branson, MONPI 1679915664

Payments from drug & device makers

$5,897in general payments, 2019–2025

Across 392 payments — averaging $15.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Lilly USA, LLC$753
  • Novo Nordisk$719
  • Kowa Pharmaceuticals America, Inc.$414
  • Boehringer Ingelheim$274
  • Abbott$224
  • plus $2K from 27 others

What the payments were for

  • Food & beverage$5,897100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,897 in reported general payments places this provider in the 95th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Medicare billing

Part B allowed, 2024
$72,443
Medicare patients
274
Services billed
1,511

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide40$58,428
EliquisApixaban45$58,320
JardianceEmpagliflozin51$58,007
TrulicityDulaglutide47$53,092
TymlosAbaloparatide12$37,061
MounjaroTirzepatide26$27,241
FarxigaDapagliflozin Propanediol27$26,532
Breztri AerosphereBudesonide/Glycopyr/Formoterol23$22,699
VascepaIcosapent Ethyl31$13,604
Xigduo XrDapaglifloz Propaned/Metformin13$12,023
JanuviaSitagliptin Phosphate11$8,631
Spiriva RespimatTiotropium Bromide13$6,857
Celecoxib52$2,496
Oxybutynin Chloride16$2,433
Advair DiskusFluticasone Propion/Salmeterol13$2,048

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$753$80,33373 claims
Boehringer IngelheimJardiance, Spiriva Respimat$274$64,86564 claims
Novo NordiskOzempic$719$58,42840 claims
PfizerEliquis$137$58,32045 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,394$49,23150 claims
Radius Health, Inc.Tymlos$97$37,06112 claims
MerckJanuvia$44$8,63111 claims
AbbVieSynthroid$110$99216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,812 family providers in Missouri.

Other family in Branson

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →